Business / Finance

RSS

EpiCept announces results of 2011 stockholders annual meeting

EpiCept Corporation announced today the results of its 2011 Annual Meeting of Stockholders held on June 14, 2011.

20 Jun 2011

GenMark prices public offering of common stock

GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing proprietary eSensor detection technology, announced today the pricing of a public offering of 7,065,600 shares of its common stock at a price to the public of $4.25 per share.

17 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

CBAI acquires assets of NeoCells for $320,000

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it has acquired the assets of NeoCells, a subsidiary of ViviCells International, Inc., Evanston, Illinois, through a foreclosure procedure at a purchase price of $320,000.

17 Jun 2011

Enterologics to acquire BioBalance from NYHC

Enterologics, Inc. announced today that it is acquiring all the shares of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc.

17 Jun 2011

UHN, Toronto Rehab receive Board approval for integration

The Toronto Rehabilitation Institute (Toronto Rehab) and University Health Network (UHN) Boards of Directors today gave final approval to the integration of Toronto Rehab with UHN today which is the final step in a process that began in April, 2011.

17 Jun 2011

Lumosity announces $32.5M Series C financing round

Lumosity announced today it has raised $32.5 million in Series C financing. Lumosity leverages cutting-edge neuroscience to create games and exercises that improve core cognitive abilities and enable users to remember more, think faster and perform better at work and school.

16 Jun 2011

ClinTec opens fully registered offices in China, Singapore and Thailand for clinical research

UK based Global Clinical Research Organisation (CRO), ClinTec International has continued its international expansion by opening fully registered offices in China, Singapore and Thailand - consolidating its presence in the Asia Pacific region.

16 Jun 2011

Patient Access Solutions announces 67% reduction in company's total liability

Patient Access Solutions, Inc., A provider of healthcare/financial processing technologies for the healthcare and home care industry today announced that the company has reduced its outstanding liabilities by $1,768,189.00.

16 Jun 2011

Merge prices $52M senior secured notes due 2015

Merge Healthcare Incorporated today announced the pricing of its $52 million aggregate principal amount of 11.75% senior secured notes due 2015.

16 Jun 2011

Spectrum board authorizes $25 million stock repurchase program

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012.

15 Jun 2011

Cardinal Health renews pharmaceutical distribution agreement with Prime Therapeutics

Cardinal Health today announced that it has signed a renewed, three-year agreement with Prime Therapeutics, one of the nation's leading pharmacy benefit managers, to continue to serve as its primary pharmaceutical supply chain partner for its mail-service pharmacy, PrimeMail®.

15 Jun 2011

Russian CRO market expects to report yearly growth of 9.5% between 2009 and 2017

The Russian CRO market is set to emerge as a distinct competitor in the global CRO market, expected to report yearly growth of 9.5% between 2009 and 2017, according to a new report on companiesandmarkets.com.

15 Jun 2011

Spinal Modulation completes Series D financing for $30 million

Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.

15 Jun 2011

OncoSec Medical third quarter net loss increases to $491,000

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, today reported financial results for the quarter ended April 30, 2011.

15 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Rotech commences $283.5 million registered exchange offer

Rotech Healthcare Inc., one of the largest providers of home medical equipment and related products and services, announced today that it has commenced a registered exchange offer to exchange up to $283.5 million aggregate principal amount of its Senior Second Lien Notes due 2018 which have been registered under the Securities Act of 1933, as amended for an equal principal amount of its outstanding Senior Second Lien Notes due 2018, which were issued in a private placement.

15 Jun 2011

HTX provides $750,000 funding to Profound Medical through Technology Assessment Program

HTX, a member of the Canadian Venture Capital Association, announced today it provided $750,000 in financing to Profound Medical Inc. through their Technology Assessment Program.

15 Jun 2011

APP announces $38 million expansion of New York manufacturing facility

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today a $38 million expansion of its Grand Island, New York manufacturing facility.

15 Jun 2011

Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011

Akela Pharma, Inc., a drug development company with its lead product, Fentanyl TAIFUN, being developed for the treatment of breakthrough cancer pain and the company's wholly owned subsidiary, PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three months and year ended March 31, 2011.

15 Jun 2011